PE20201163A1 - Composiciones y tratamientos para el trastorno del sueno - Google Patents

Composiciones y tratamientos para el trastorno del sueno

Info

Publication number
PE20201163A1
PE20201163A1 PE2019002553A PE2019002553A PE20201163A1 PE 20201163 A1 PE20201163 A1 PE 20201163A1 PE 2019002553 A PE2019002553 A PE 2019002553A PE 2019002553 A PE2019002553 A PE 2019002553A PE 20201163 A1 PE20201163 A1 PE 20201163A1
Authority
PE
Peru
Prior art keywords
treatments
compositions
sleep disorder
pharmaceutical composition
extract
Prior art date
Application number
PE2019002553A
Other languages
English (en)
Inventor
Mara Gordon
Stewart Smith
Stewart Washer
Patrizia Washer
Harry Karelis
Original Assignee
Zelda Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902338A external-priority patent/AU2017902338A0/en
Application filed by Zelda Therapeutics Operations Pty Ltd filed Critical Zelda Therapeutics Operations Pty Ltd
Publication of PE20201163A1 publication Critical patent/PE20201163A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La invencion se refiere a una composicion farmaceutica que comprende un extracto de Cannabis y opcionalmente uno o mas portadores, diluyentes, adyuvantes, excipientes o cualquier combinacion de los mismos farmaceuticamente aceptables, el extracto de Cannabis comprende una fraccion de cannabinoides que comprende delta9-Tetrahidrocannabinol (THC), Cannabidiol (CBD) y Cannabinol (CBN) y una fraccion de terpenos en una cantidad de al menos 3 % en peso del extracto. La invencion tambien se refiere a metodos para tratar trastornos del sueno mediante el uso de esta composicion farmaceutica.
PE2019002553A 2017-06-19 2018-06-19 Composiciones y tratamientos para el trastorno del sueno PE20201163A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017902338A AU2017902338A0 (en) 2017-06-19 Sleep Disorder Composition and Treatment Thereof
AU2017904818A AU2017904818A0 (en) 2017-11-29 Sleep Disorder Compositions and Treatments Thereof
PCT/AU2018/050604 WO2018232448A1 (en) 2017-06-19 2018-06-19 COMPOSITION AGAINST SLEEP APNEA AND RELATED TREATMENTS

Publications (1)

Publication Number Publication Date
PE20201163A1 true PE20201163A1 (es) 2020-10-28

Family

ID=62947713

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019002553A PE20201163A1 (es) 2017-06-19 2018-06-19 Composiciones y tratamientos para el trastorno del sueno

Country Status (16)

Country Link
US (2) US20210145910A1 (es)
EP (1) EP3641754A4 (es)
JP (1) JP2020524151A (es)
KR (1) KR20200104278A (es)
CN (1) CN110944632A (es)
AU (2) AU2018100837B4 (es)
BR (1) BR112019026877A2 (es)
CA (1) CA3065563C (es)
CL (1) CL2019003635A1 (es)
CO (1) CO2019013887A2 (es)
IL (1) IL271503A (es)
MX (1) MX2019015315A (es)
NZ (1) NZ759963A (es)
PE (1) PE20201163A1 (es)
SG (1) SG11201912380XA (es)
WO (1) WO2018232448A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
EP3864000A4 (en) 2018-10-10 2022-08-10 Treehouse Biosciences, Inc. CANNABIGEROL SYNTHESIS
CA3027876A1 (en) * 2018-12-18 2020-06-18 Tetra Bio-Pharma Cannabis compositions and methods
NL2022616B1 (en) * 2019-02-21 2020-09-18 Patrick Alexander Unger Cannabigerol and pharmaceutical compositions comprising cannabigerol for use in the treatment of insomnia
US10946054B1 (en) * 2019-10-08 2021-03-16 Jenny's Rose, LLC Therapeutic cannabis extracts
WO2021178579A1 (en) * 2020-03-03 2021-09-10 Alte Verde Llc Cannabis treatment of insomnia, pain, and skin conditions
WO2021181248A1 (en) * 2020-03-09 2021-09-16 This Works Products Limited Compositions comprising functional fragrances and cannabis-derived compounds
CN112057894A (zh) * 2020-09-08 2020-12-11 云南工麻生物科技有限公司 一种提取大麻二酚的方法
CN113143995A (zh) * 2021-01-21 2021-07-23 龙麻(上海)医药研发有限责任公司 一种大麻提取物舌下片及其制备工艺和应用
CN112999218A (zh) * 2021-01-21 2021-06-22 龙麻(上海)医药研发有限责任公司 一种具有镇静助眠功效的组合物及用途
CN112791151B (zh) * 2021-02-20 2022-04-01 山东新稀宝股份有限公司 一种具有改善睡眠功能的组合物及应用
DK181329B1 (en) 2021-05-04 2023-08-16 Cs Medica As Nasal sleep spray composition, method for its provision, and receptacle and kit comprising said composition
US20220401407A1 (en) * 2021-06-09 2022-12-22 Demetrix, Inc. Regulation of the sleep/wake cycle using cannabinoid compounds
AU2023212130A1 (en) * 2022-01-27 2024-05-23 DEFINED RESEARCH, Inc. A cannabidiol (cbd) and terpene formulation that increases restorative sleep in humans

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949582B1 (en) * 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
EP3007714A1 (en) * 2013-06-13 2016-04-20 Cannabis Science International Holding BV Composition for the treatment of neurobehavioral disorders
CN103355391A (zh) * 2013-08-13 2013-10-23 汕头大学医学院第一附属医院 一种五味健脑益智饼及其制备方法
CA3135893C (en) * 2014-10-21 2023-11-14 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
WO2016191651A1 (en) * 2015-05-28 2016-12-01 Insys Development Company, Inc. Stable cannabinoid formulations
IL246790A0 (en) * 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
CA3031810A1 (en) * 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
US9649349B1 (en) * 2017-01-19 2017-05-16 Metamorphic Alchemy & Distillations, Inc. System and method for producing a terpene-enhanced cannibinoid concentrate
US20200179269A1 (en) * 2017-03-20 2020-06-11 Kanabo Research Ltd. Vaporizable compositions comprising cannabinol
US20180352848A1 (en) * 2017-06-07 2018-12-13 NC3 Systems Smokable cannabis-based product with reduced psychoactive effects
CA3089994A1 (en) * 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder

Also Published As

Publication number Publication date
CO2019013887A2 (es) 2020-04-01
JP2020524151A (ja) 2020-08-13
BR112019026877A2 (pt) 2020-06-30
MX2019015315A (es) 2020-02-17
CA3065563A1 (en) 2018-12-27
NZ759963A (en) 2022-07-01
KR20200104278A (ko) 2020-09-03
AU2018100837B4 (en) 2019-02-21
AU2018286647A1 (en) 2020-01-16
US20210145910A1 (en) 2021-05-20
AU2018286647B2 (en) 2024-03-28
CN110944632A (zh) 2020-03-31
EP3641754A4 (en) 2021-03-10
CA3065563C (en) 2023-06-13
CL2019003635A1 (es) 2020-06-19
EP3641754A1 (en) 2020-04-29
IL271503A (en) 2020-02-27
US20230270808A1 (en) 2023-08-31
AU2018100837A4 (en) 2018-07-26
WO2018232448A1 (en) 2018-12-27
SG11201912380XA (en) 2020-01-30

Similar Documents

Publication Publication Date Title
PE20201163A1 (es) Composiciones y tratamientos para el trastorno del sueno
PE20230607A1 (es) Composicion de cannabis
PE20200726A1 (es) Composicion de cannabis
CL2019000268A1 (es) Composición de cannabis.
CL2020003368A1 (es) Composicion y metodo para tratar el dolor
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
CL2021002646A1 (es) Métodos y composiciones para su uso en el tratamiento del cáncer sin efectos psicosactivos
UY37271A (es) Composiciones nasales de cannabinoides
MX2020007784A (es) Uso de cannabinoides en el tratamiento de la epilepsia.
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
CR20180493A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
MX2020004232A (es) Composiciones de cannabinoides y sus metodos de uso.
CL2021002401A1 (es) Extractos bacterianos estables como fármacos
CO2021001059A2 (es) Composición de cannabinoides y método para tratar el ptsd y/o la ansiedad
CO2021001057A2 (es) Composición y método para el ahorro de opioides
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
CO2023000130A2 (es) Composición y método para el tratamiento del dolor crónico
CO2019000604A2 (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d
ECSP21010874A (es) Piridopirimidinas como inhibidores del receptor de histamina h4
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
PE20211198A1 (es) Metodos y formulaciones para tratar nauseas y vomitos inducidos por quimioterapia
CO2021006279A2 (es) Métodos y tratamientos para la disfunción eréctil